The Drug Etiology of Agranulocytosis and Aplastic Anemia

DRUG INDUCED AGRANULOCYTOSIS AND APLASTIC ANEMIA: GENERAL CONSIDERATIONS: The concept of drug safety Agranulocytosis and aplastic anemia as drug-induced diseases Evidence for the drug induction of agranulocytosis Evidence for the drug induction of aplastic anemia STRATEGIES FOR OBTAINING INFORMATION ABOUT DRUG EFFECTS: Benefit, risk, the present study THE DISEASES (by Herman Heimpel): Agranulocytosis, Aplastic anemia THE DESIGN OF THE STUDY: Objectives, definition of cases, study base, sample size estimates, methodological considerations in the collection of data METHODS: Definition and ascertainment of cases, selection of controls, data collection, data analysis THE STUDY EXPERIENCE: Origins of the study, pilot study, changes in the study population, completeness of case ascertainment, definition of onset for cases of agranulocytosis, interim analyses THE STUDY POPULATION: Agranulocytosis, Aplastic anemia, Controls, Summary INCIDENCE OF AGRANULOCYTOSIS: The study base: overall incidence, community-acquired agranulocytosis, comments INCIDENCE OF APLASTIC ANEMIA: The study base: overall incidence, incidence according to various factors, comments NONNARCOTIC ANALGESIC AND NONSTEROIDAL ANTI-FLAMMATORY DRUGS The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion ANTI-INFECTIVE DRUGS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion ANTITHYROID DRUGS: The drugs, specific methods, results, summary of results and considerations of validity, comments, conclusion CARDIOVASCULAR DRUGS AND DIURETICS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion PSYCHOTROPIC DRUGS AND ANTIHISTAMINES: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion MISCELLANEOUS DRUGS: The drugs, specific methods, results, summary of results and consideration of validity, comments, conclusion FACTORS OTHER THAN DRUGS: Introduction, specific methods, results, summary of results and consideration of validity, comments, conclusion GENERAL CONCLUSIONS: Risk estimation for diseases with multiple causes Etiologically relevant risk intervals Regional variation of drug-induced agranulocytosis The strengths and limitations of the present study Concluding remarks. Appendices Index of Drug names.